Cue More Drama in Teva's Boardroom as its CEO Announcement Nears
![](/46/pdcnewsitem/02/93/20/zDgQoyftwO9hOYB.png)
It looks like new year, new CEO at Teva Pharmaceutical Industries. But even as the company appears to be on the verge of naming a replacement for former helmsman Jeremy Levin, there's still quite a bit of intrigue at the top of the company. As the Financial Times reports, shareholders are pressing for a boardroom change-up that could end with a new occupant for the chairman's seat.
According to Israeli newspaper Globes, Erez Vigodman is first in line for the top spot at the Israeli company. Vigodman, CEO of Israel's biggest agrochemicals company and the former leader of Israeli food giant Strauss Group, has served on Teva's board since 2009 and has been considered a front-runner for the position since the search began. Citi Research expects the CEO announcement to precede the company's 6 February financial report for 2014, and Israeli news source TheMarker predicts it could come as early as the JP Morgan Healthcare Conference that begins 13 January.
Strictly speaking, Vigodman lacks experience in the pharma industry — but then again, as the Financial Times notes, so does the rest of Teva's board. And that's one reason Israeli entrepreneur and shareholder Benny Landa has set out to rally support for a larger shakeup. In a December email sent to key shareholders, Landa called for "significant board leadership changes" at the generics maker, the FT reports.
"I don't know if this board is able to attract a world class CEO to lead Teva, but with higher standards of corporate governance and a pharma-seasoned board of directors, at least the new CEO will stand a better chance than his predecessor!" he wrote, as quoted by the FT.
Of course, the question of boardroom personnel is especially important in light of the disagreement that led to Levin's exit in October. Chairman Phillip Frost described differences between the two sides as "subtle," rather than a direct butting of heads over Levin's strategy to get the struggling company back on track. But others say the board interference — particularly from Florida-based Frost — was more extreme. "Levin would have to go to Miami to kiss the ring each time he wanted a decision," an external consultant told the FT.
Landa's proposed changes also involve slimming down to 12 directors from 16 — a move Globes calls a possible threat to Frost's job.
Landa told shareholders that the directors themselves would propose his recommended changes this month. But the company told the FT that "no discussions took place with institutional stakeholders on behalf of Teva's board of directors."
The company certainly has plenty to do in the meantime, as it implements a layoffs-heavy cost-cutting effort and prepares to lose patent protection on its leading moneymaker, the multiple sclerosis treatment Copaxone, in May. And as Citi analyst Liav Abraham wrote in a note seen by Reuters, while Vigodman may not have specific pharma experience, after streamlining his current company and selling its controlling interest to China, he does have experience righting a listing ship.
"Although investors may express some skepticism if Mr Vigodman is selected due to his lack of experience in the pharma industry, we note his successful record in the execution of turnaround strategies at large publicly traded companies, which is relevant for Teva as the company faces the loss of exclusivity of Copaxone and implementation of an extensive $2 billion cost reduction program," he said.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance